Edition:
United Kingdom

Loxo Oncology Inc (LOXO.OQ)

LOXO.OQ on NASDAQ Stock Exchange Global Market

129.51USD
24 Apr 2018
Change (% chg)

$-3.55 (-2.67%)
Prev Close
$133.06
Open
$133.67
Day's High
$135.00
Day's Low
$128.85
Volume
102,630
Avg. Vol
152,631
52-wk High
$138.53
52-wk Low
$42.11

Chart for

About

Loxo Oncology, Inc. is a biopharmaceutical company. The Company is focused on development of medicines for patients with genetically defined cancers. The Company's pipeline focuses on cancers that are dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect.... (more)

Overall

Beta: --
Market Cap(Mil.): $2,616.89
Shares Outstanding(Mil.): 29.85
Dividend: --
Yield (%): --

Financials

  LOXO.OQ Industry Sector
P/E (TTM): -- 84.02 32.74
EPS (TTM): -4.18 -- --
ROI: -31.65 1.58 14.38
ROE: -31.65 2.41 16.07

BRIEF-Veracyte Announces Precision Medicine Collaboration With Loxo Oncology

* VERACYTE ANNOUNCES PRECISION MEDICINE COLLABORATION WITH LOXO ONCOLOGY

11 Apr 2018

Loxo, Illumina to partner for diagnostic tool targeting cancer

Drug developer Loxo Oncology said on Tuesday it is partnering with genetic testing company Illumina Inc on a diagnostic tool that will work with Loxo's larotrectinib and another one of its experimental cancer drugs, across tumor types.

10 Apr 2018

UPDATE 1-Loxo, Illumina to partner for diagnostic tool targeting cancer

April 10 Drug developer Loxo Oncology said on Tuesday it is partnering with genetic testing company Illumina Inc on a diagnostic tool that will work with Loxo's larotrectinib and another one of its experimental cancer drugs, across tumor types.

10 Apr 2018

Loxo and Illumina in partnership over diagnostic for cancer drug

Loxo Oncology is partnering with genetic testing company Illumina Inc to use Illumina's diagnostic tool alongside larotrectinib, the drug developer's potential blockbuster drug, the companies said on Tuesday.

10 Apr 2018

Loxo and Illumina in partnership over diagnostic for cancer drug

April 10 Loxo Oncology is partnering with genetic testing company Illumina Inc to use Illumina's diagnostic tool alongside larotrectinib, the drug developer's potential blockbuster drug, the companies said on Tuesday.

10 Apr 2018

BRIEF-Loxo Oncology And Illumina To Partner On Developing Pan Cancer Companion Diagnostics

* LOXO ONCOLOGY AND ILLUMINA TO PARTNER ON DEVELOPING NEXT-GENERATION SEQUENCING-BASED PAN-CANCER COMPANION DIAGNOSTICS

10 Apr 2018

High-flying biotech Loxo tempers bullish view for cancer drug

STAMFORD, Connecticut In record time, Loxo Oncology developed a novel drug for a wide variety of tumors that share a rare mutation. It recently struck a partnership with Germany's Bayer . Its stock tripled in the past year.

03 Apr 2018

FOCUS-High-flying biotech Loxo tempers bullish view for cancer drug

STAMFORD, Connecticut, April 3 In record time, Loxo Oncology developed a novel drug for a wide variety of tumors that share a rare mutation. It recently struck a partnership with Germany's Bayer. Its stock tripled in the past year.

03 Apr 2018

BRIEF-Loxo Oncology Completes Rolling Submission Of New Drug Application To U.S. Food And Drug Administration

* LOXO ONCOLOGY COMPLETES ROLLING SUBMISSION OF NEW DRUG APPLICATION TO U.S. FOOD AND DRUG ADMINISTRATION FOR LAROTRECTINIB FOR THE TREATMENT OF TRK FUSION CANCER Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)

26 Mar 2018

BRIEF-Loxo Oncology Reports Quarterly Non-Gaap Net Loss Per Share $1.24

* LOXO ONCOLOGY REPORTS FOURTH QUARTER AND YEAR-END 2017 FINANCIAL RESULTS

01 Mar 2018

Earnings vs. Estimates